CO154 Are Biosimilars Equivalent to Originator Molecules in the Real-World? Assessments of Efficacy, Toxicity, and Tolerability of Infliximabs in Infliximab-Naïve Patients with Rheumatoid Arthritis
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.227
https://www.valueinhealthjournal.com/article/S1098-3015(23)00327-3/fulltext
Title :
CO154 Are Biosimilars Equivalent to Originator Molecules in the Real-World? Assessments of Efficacy, Toxicity, and Tolerability of Infliximabs in Infliximab-Naïve Patients with Rheumatoid Arthritis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00327-3&doi=10.1016/j.jval.2023.03.227
First page :
Section Title :
Open access? :
No
Section Order :
11620